16,666 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Purchased by Argentarii LLC

Argentarii LLC bought a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,666 shares of the company’s stock, valued at approximately $160,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Van ECK Associates Corp bought a new position in MiMedx Group during the 4th quarter valued at about $40,000. Point72 DIFC Ltd lifted its stake in MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after acquiring an additional 4,275 shares during the period. Entropy Technologies LP bought a new position in MiMedx Group during the 3rd quarter valued at about $64,000. Orion Capital Management LLC lifted its stake in MiMedx Group by 46.3% during the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock valued at $69,000 after acquiring an additional 3,700 shares during the period. Finally, SkyView Investment Advisors LLC lifted its stake in MiMedx Group by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after acquiring an additional 3,000 shares during the period. Institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Price Performance

NASDAQ MDXG opened at $7.89 on Monday. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The firm has a market capitalization of $1.16 billion, a P/E ratio of 14.35 and a beta of 1.97. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The company has a 50-day moving average price of $8.60 and a 200-day moving average price of $7.78.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The firm had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. Equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.